AstraZeneca gets marketing permission for cancer drug in India

New Delhi: AstraZeneca Pharma India on Thursday said it has received approval from the Indian drug regulator to market Durvalumab, a cancer treatment medicine, in the country.

The company has received import and market permission for Durvalumab from the Drug Controller General of India (DCGI), AstraZeneca Pharma India said in a statement.

The approval paves the way for the company to launch the product in the country, it added.

Durvalumab is indicated as a treatment option for patients with locally advanced, unresectable non-small cell lung Cancer (NSCLC) and metastatic urothelial carcinoma.

“The import and market permission for Durvalumab for unresectable stage III Non-Small Cell Lung Cancer (NSCLC) and locally advanced or metastatic urothelial carcinoma is a significant milestone for patients who have currently limited treatment options,” AstraZeneca Pharma India Managing Director Gagan Singh said.

In India, around one third of patients with NSCLC are present with stage III disease and the company is happy to bring the first immunotherapy into this setting for patients, he added.

  • Related Posts

    • Pharma
    • July 24, 2025
    • 105 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 186 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra